Patent ID: 9480664
Filing Date: 2016-11-01
CPC Classification: A61K

Claim Text:
1. A pharmaceutical composition comprising an effective amount of a COX-2 inhibitor to inhibit cancer cell growth in a subject in need thereof in combination with a 20-Hydroxyeicosatetraenoic acid (20-HETE) antagonist in an effective amount to reduce or inhibit side effects of the COX-2 inhibitor in the subject, wherein the COX-2 inhibitor is selected from the group consisting celecoxib, rofecoxib, etoricoxib, valdecoxib, 4-[5-(4-methylphenyl)-3-(methylselenocyano)-1H-pyrazol-1-yl]benzene-sulfonamide, 4-[5-(4-(methylselenomethylene)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-sulfonamide and 2,5-dimethyl-celecoxib and wherein the 20-HETE antagonist is selected from the group consisting of 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid (WIT002), N-Hydroxy-N′-(4-butyl-2-methylphenyl)formamidine (HET0016), 17-octadecynoic acid (17-ODYA), N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS), dibromododec-11-enoic acid (DDBB), N-(3-Chloro-4-morpholin-4-yl)Phenyl-N′-hydroxyimido formamide (TS011), 20-hydroxyeicosa-6(Z),15 (Z)-dienoic acid (6-,15-,20-HEDE) and (N-[20-hydroxyeicosa-5 (Z), and 14 (Z)-dienoic acid (5, 14, 20-HEDGE).